MSA NJ

03/19/2026

A new experimental stem cell therapy for people with MSA–P (Parkinsonian type) has been approved by regulators in the United States and China to begin clinical trials. The therapy aims to replace or repair damaged brain cells that are lost in the disease, which could potentially improve symptoms. While this treatment is still in the early testing stages (Phase 1), these trials are an important step toward developing new treatments for MSA.

Regulators in the U.S. and China have granted Xellsmart permission to start clinical testing of its experimental stem cell therapy in MSA-P.

03/16/2026

This study looked at a structure in the brain called the choroid plexus, which helps produce and regulate the fluid around the brain. Researchers found that people with MSA tend to have a smaller choroid plexus, which was linked to greater brain shrinkage and reduced brain activity. Further research could help determine whether changes in this structure may serve as a biomarker for disease progression in MSA.

The choroid plexus (CP), a component of the glymphatic system, is essential in homeostasis and producing cerebrospinal fluid. Role of CP in multiple system atrophy (MSA) remains unclear. This study aimed to investigate the implication of the CP in MSA. This retrospective cross-sectional study includ...

03/15/2026

March is MSA Awareness month. This month we recognize the strength and resilience of people with MSA and caregivers. Raising awareness helps support research and bring us closer to better treatments in the future.

03/03/2026

Caregivers— Have you grounded yourself today? With balancing different tasks it’s easy to get caught in the motions.

Try this:

“Place a Hand on Your Chest or Stomach

As you continue to breathe, feel the rise and fall of your body. Let your hand remind you that you have a body with needs and not just responsibilities. “ (Smith, 2026)

Full Article with more grounding techniques:

https://www.psychologytoday.com/us/blog/unpacking-therapy-culture/202601/caregiver-burnout-in-the-age-of-self-helpy t

Understand the complex issue of caregiver burnout and how to effectively address it.

01/11/2026

Foralumab, an antibody currently being tested in patients with MSA, MS, and Alzheimer’s disease, has continued to demonstrate no serious adverse effects. The drug is in Phase 2a clinical trials and is intended to reduce the inflammatory responses associated with these diseases.

Linked is an article for a longer read.

https://multiplesclerosisnewstoday.com/news-posts/2025/1/5/foralumab-nasal-spray-shows-long-term-safety-spms-data/

https://clinicaltrials.gov/study/NCT06868628

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, data show.

12/31/2025

Wishing everyone a new year that is filled with hope and love. May you find joy in even the smallest of things and peace in all you do. Have a wonderful holiday and good new year ahead.

12/03/2025

As the official giving season is underway, please consider MSANJ. Any donation will help us to continue our mission, providing support and awareness for patients and families facing life with MSA. As a 501(c)(3), all donations are tax deductible. Visit our website to learn more or make an online donation. Thank you.

Run entirely by volunteers, MSA NJ needs donations to provide educational and support programs to the multiple system atrophy community. Please consider a one-time or reoccurring donation to support our mission.

11/27/2025

10/04/2025

MSA Day 2025:
Lighting a candle in honor of the inspiration for MSA NJ, our MSA angel and beautiful mother, Dolores Roemer; lost to Multiple System Atrophy on Mother's Day 2009. Love and miss you, Mommy. 💜

10/02/2025

Remember - World MSA Day is tomorrow. For all our warriors and angels - we continue our support to fight this disease.

09/22/2025

More recent developments, Emrusolmin being granted the Fast Track Designation by the FDA which is currently in its Phase 2 trial.

There are currently no FDA-approved treatments that address the underlying disease progression of MSA.